Peoples Financial Services CORP. cut its stake in Pfizer, Inc. (NYSE:PFE) by 1.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 120,630 shares of the biopharmaceutical company’s stock after selling 1,488 shares during the period. Pfizer comprises about 2.5% of Peoples Financial Services CORP.’s portfolio, making the stock its 7th largest position. Peoples Financial Services CORP.’s holdings in Pfizer were worth $4,084,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Acadian Asset Management LLC increased its position in shares of Pfizer by 2.6% in the third quarter. Acadian Asset Management LLC now owns 2,688,446 shares of the biopharmaceutical company’s stock valued at $91,057,000 after buying an additional 68,300 shares during the last quarter. 1st Global Advisors Inc. increased its position in shares of Pfizer by 9.8% in the third quarter. 1st Global Advisors Inc. now owns 110,523 shares of the biopharmaceutical company’s stock valued at $3,743,000 after buying an additional 9,846 shares during the last quarter. Parsec Financial Management Inc. increased its position in shares of Pfizer by 1.8% in the third quarter. Parsec Financial Management Inc. now owns 14,195 shares of the biopharmaceutical company’s stock valued at $481,000 after buying an additional 257 shares during the last quarter. Alpha Windward LLC increased its position in shares of Pfizer by 0.5% in the third quarter. Alpha Windward LLC now owns 8,315 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 40 shares during the last quarter. Finally, Crossvault Capital Management LLC increased its position in shares of Pfizer by 0.9% in the third quarter. Crossvault Capital Management LLC now owns 138,984 shares of the biopharmaceutical company’s stock valued at $4,707,000 after buying an additional 1,277 shares during the last quarter. 68.39% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer, Inc. (NYSE:PFE) opened at 32.52 on Friday. The firm has a 50-day moving average price of $32.41 and a 200-day moving average price of $33.71. Pfizer, Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The stock has a market cap of $197.34 billion, a price-to-earnings ratio of 32.65 and a beta of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.62 by $0.01. The firm had revenue of $13.05 billion for the quarter, compared to analysts’ expectations of $13.05 billion. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. The business’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.60 EPS. Equities research analysts expect that Pfizer, Inc. will post $2.42 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 1st. Stockholders of record on Friday, February 3rd will be paid a dividend of $0.32 per share. The ex-dividend date is Wednesday, February 1st. This represents a $1.28 annualized dividend and a dividend yield of 3.94%. This is a positive change from Pfizer’s previous quarterly dividend of $0.30. Pfizer’s dividend payout ratio (DPR) is currently 106.20%.

WARNING: This article was posted by Daily Political and is the propert of of Daily Political. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international copyright law. The original version of this article can be accessed at http://www.dailypolitical.com/2017/01/14/peoples-financial-services-corp-has-4084000-stake-in-pfizer-inc-pfe.html.

Several analysts recently weighed in on PFE shares. Guggenheim started coverage on shares of Pfizer in a report on Friday, December 2nd. They issued a “neutral” rating on the stock. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Tuesday, January 3rd. Bank of America Corporation reiterated a “buy” rating and issued a $40.00 price target on shares of Pfizer in a report on Tuesday, September 27th. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 price target on the stock. in a report on Thursday, October 13th. Finally, Argus reiterated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a report on Tuesday, October 4th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $37.30.

In other news, insider Albert Bourla sold 18,390 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $30.05, for a total transaction of $552,619.50. Following the transaction, the insider now owns 149,199 shares in the company, valued at $4,483,429.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Anthony J. Maddaluna sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total value of $330,000.00. Following the transaction, the insider now owns 112,087 shares in the company, valued at approximately $3,698,871. The disclosure for this sale can be found here. Insiders own 0.07% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.